Is there a way out?
Now that all of the insulin pump companies have reported here is what we know.
Insulet has firmly established themselves as the leader in the category while Medtronic and Tandem are struggling to remain relevant.
So, the question becomes barring a sale how do Medtronic and Tandem remain relevant? How do they effectively compete without crippling their revenue model?
Let’s make something very clear as it’s a myth being spread by both Medtronic and Tandem new technology is NOT the answer. The 780G from Medtronic and the Mobi from Tandem will NOT CHANGE ANYTHING. As good as . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.